Julian Baker’s Biogen BIIB Stock Holding History

Julian Baker’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-16,500	Closed	-$4.51M	–	121
2017 Q1	$4.51M	Hold	16,500	–	–	0.04%	67
2016 Q4	$4.68M	Buy	+16,500	New	+$4.89M	0.05%	66

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Julian Baker's BIIB Position: Q2 2017 in Review

Julian Baker sold out of Biogen (BIIB) in Q2 2017, closing a stake of 16,500 shares — an estimated $4.51M sold.

Julian Baker first reported a position in BIIB in Q4 2016 and held it in 2 quarters. The position peaked at $4.68M in Q4 2016. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

Julian Baker reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
Julian Baker sold 16,500 Biogen shares in Q2 2017, an estimated $4.51M.
Julian Baker first reported a position in Biogen in Q4 2016 and held it in 2 quarters.
Julian Baker's Biogen position peaked at $4.68M in Q4 2016.
992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Baker Bros. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.